Evidence map›Paper›PMID 36947528›Full record

ArticlePloS one2023

Telomere length and brain imaging phenotypes in UK Biobank.

Anya Topiwala, Thomas E Nichols, Logan Z J Williams, Emma C Robinson, Fidel Alfaro-Almagro, Bernd Taschler, Chaoyue Wang, Christopher P Nelson, Karla L Miller, Veryan Codd and 2 more

Open access · goldFull text read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. c-Jun N-terminal kinase signaling in aging.Frontiers in aging neuroscience · 2024
    Review
  16. Article
  17. Review
  18. Review
  19. Cognitive Impairment in Multiple Sclerosis.Bioengineering (Basel, Switzerland) · 2023
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Anya TopiwalaNuffield Department Population Health, Big Data Institute, University of Oxford, Oxford, United Kingdom.ORCID 0000-0002-8408-0372
Thomas E NicholsNuffield Department Population Health, Big Data Institute, University of Oxford, Oxford, United Kingdom.ORCID 0000-0002-4516-5103
Logan Z J WilliamsCentre for the Developing Brain, School of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom.
Emma C RobinsonCentre for the Developing Brain, School of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom.
Fidel Alfaro-AlmagroNuffield Department of Clinical Neurosciences, Wellcome Centre for Integrative Neuroimaging (WIN FMRIB), University of Oxford, Oxford, United Kingdom.
Bernd TaschlerNuffield Department of Clinical Neurosciences, Wellcome Centre for Integrative Neuroimaging (WIN FMRIB), University of Oxford, Oxford, United Kingdom.ORCID 0000-0001-6574-4789
Chaoyue WangWellcome Centre for Integrative Neuroimaging (WIN FMRIB), Oxford University, Oxford, United Kingdom.
Christopher P NelsonDepartment of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom.
Karla L MillerWellcome Centre for Integrative Neuroimaging (WIN FMRIB), Oxford University, Oxford, United Kingdom.
Veryan CoddDepartment of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom.
Nilesh J SamaniDepartment of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom.
Stephen M SmithWellcome Centre for Integrative Neuroimaging (WIN FMRIB), Oxford University, Oxford, United Kingdom.
University of Oxford · GBUniversity of Leicester · GBKing's College London · GB

Funding

Spatial inference methods for image analysisR01EB026859 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SCHWARTZMAN, ARMIN · 2019 to 2022
$1.7M
Biotechnology and Biological Sciences Research CouncilBritish Heart Foundation CH/1996001/9454Department of Health BRC-1215-20010Department of Health BRC-1215-20014Medical Research Council MC_PC_15067Medical Research Council MC_PC_17224Medical Research Council MC_PC_17228Medical Research Council MC_PC_21035Medical Research Council MC_QA137853Medical Research Council MR/M012816/1NIBIB NIH HHS R01 EB026859Wellcome TrustWellcome Trust 100309/Z/12/ZWellcome Trust 202788/Z/16/ZWellcome Trust 215573/Z/19/ZWellcome Trust 216462/Z/19/Z
6 · The paper itself

Abstract

Telomeres form protective caps at the ends of chromosomes, and their attrition is a marker of biological aging. Short telomeres are associated with an increased risk of neurological and psychiatric disorders including dementia. The mechanism underlying this risk is unclear, and may involve brain structure and function. However, the relationship between telomere length and neuroimaging markers is poorly characterized. Here we show that leucocyte telomere length (LTL) is associated with multi-modal MRI phenotypes in 31,661 UK Biobank participants. Longer LTL is associated with: i) larger global and subcortical grey matter volumes including the hippocampus, ii) lower T1-weighted grey-white tissue contrast in sensory cortices, iii) white-matter microstructure measures in corpus callosum and association fibres, iv) lower volume of white matter hyperintensities, and v) lower basal ganglia iron. Longer LTL was protective against certain related clinical manifestations, namely all-cause dementia (HR 0.93, 95% CI: 0.91-0.96), but not stroke or Parkinson's disease. LTL is associated with multiple MRI endophenotypes of neurodegenerative disease, suggesting a pathway by which longer LTL may confer protective against dementia.

Indexed as

DementiaNeurodegenerative DiseasesBiological Specimen BanksBrainHumansLeukocytesNeuroimagingPhenotypeTelomereUnited Kingdom

Identifiers

PMID36947528
PMCPMC10032499
OpenAlexW4353014912

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read13
identifiers read5
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.